Wisdom Talk

Wisdom Talk

Wisdom Talk is a sub-brand of Wisdom Forum. It has two sections: pharmaceutical frontier and science communication, which both aim to share the latest academic and industry developments with researchers and practitioners in biopharmaceuticals, and communicate popular scientific knowledge to the public. ​

Review

First Talk: An introduction to Covid-19 vaccines and vaccine research and development

Speaker: Dr Bo Ying, Founder and CEO of Abogen

On 18 January 2021, Dr Bo Ying told the story of the China’s first Covid-19 mRNA vaccine, and talked on the development trends for future vaccines and the development strategy for next-generation vaccines from the perspective of developers.

Second Talk: Precision medicine for childhood cancer​

Speaker: Dr Zhizhong Li​, Co-founder of Shiyu Children Foundation

On 29 March 2021, Dr Zhizhong Li held a discussion with students majoring in biological science and shared the application, challenges and prospects of precision medicine in paediatric cancer treatment with XJTLU teachers and students, as well as colleagues working in hospitals, new drug research and development, precision medicine, and related institutions.

Third Talk: New strategies of drug development for metabolic diseases

Speakers:
Dr Tong Wang, Chief Scientist, CGeneTech
Dr Xinyu Shao, Director of the Endocrinology Department, Dushu Lake Hospital Affiliated to Soochow University
Dr Shunfei Yan, investment manager of Innostar Capital
Dr Lei Fu, Associate Dean for Learning and Teaching, Academy of Pharmacy

On 10 June 2021, the third Wisdom Talk, themed “Drug R&D Strategy and Layout for New Generation of Glucose Metabolism and Its Derived Diseases”, gathered scientists, clinicians and financial investors in the field of glucose metabolism diseases and professors from XJTLU Wisdom Lake Academy of Pharmacy. They exchanged ideas and discussed the development direction of drugs, research and development, and clinical challenges.

Fourth Talk: Key points of equity financing negotiation for enterprises in life and the health industry

Speaker: Ziqiang Chen, Co-founder of Shanghai Jin Mao Partners

On 22 July 2021, Ziqiang Chen, a lawyer and expert in equity investment and financing in the biopharmaceutical industry, shared the core points and precautions of equity financing negotiations for enterprises in the life industry with audiences from the Suzhou biopharmaceutical industry.

Fifth Talk: A look at the drug layout of Covid-19 from antibody development

 Speaker: Dr Hui Feng, COO of Shanghai Junshi Biosciences

On 28 October 2021, Dr Feng Hui attended the fifth Wisdom Talk and shared the latest developments in Covid-19 antibody drugs. Etestulimab, developed by Junshi Biosciences in collaboration with the Institute of Microbiology, Chinese Academy of Sciences, is the first innovative biologic drug independently developed in China to be approved for use in the United States.

Sixth Talk: Tumour immunotherapy in clinical application

Speaker: Professor Jundong Zhou, Chief Physician in the Department of Radiation Oncology, Affiliated Suzhou Hospital of Nanjing Medical University

On 16 December 2021, Dr Zhou Jundong shared the clinical application of tumour immunotherapy.

Seventh Talk: High-end mass spectrometry technology enabling biopharmaceutical R&D and innovation

Speakers:
Professor Mu Wang, Executive Dean, XJTLU Wisdom Lake Academy of Pharmacy
Dr Lianshan Zhang, Vice President, Hengrui Medicine
Dr Peizhuo Zhang, Founder, President and Chief Scientist of Gene Pharma
Yu Xu, CEO, Clinical Service Center
Professor Jundong Zhou, Chief Physician in the Department of Radiation Oncology, Affiliated Suzhou Hospital of Nanjing Medical University

On 28 September 2022, XJTLU Wisdom Lake Academy of Pharmacy, together with the Science and Technology Innovation Enterprise Association and BioBAY, held the seventh session of Wisdom Talk, called “High-end mass spectrometry technology enabling biopharmaceutical R&D and innovation”. The five speakers gathered at XJTLU to explore the innovative application and support of mass spectrometry technology in biopharmaceutical research and development.